Newborn Screening for Lysosomal Storage Disorders in Experience

Journal of Pediatrics

190, 130-135

DOI: 10.1016/j.jpeds.2017.06.048

Citation Report

#	Article	IF	Citations
1	Searching for the Best Oral Treatment for Hypoglycemic Newborns. Journal of Pediatrics, 2017, 190, 10-12.	0.9	2
2	Newborn Screening for Spinal Muscular Atrophy and Lysosomal Storage Disorders Takes Advantage of Novel Therapies. Journal of Pediatrics, 2017, 190, 9-10.	0.9	2
3	Recent advances in the diagnosis and management of Gaucher disease. Expert Review of Endocrinology and Metabolism, 2018, 13, 107-118.	1.2	78
4	Newborn screening for Pompe disease: impact on families. Journal of Inherited Metabolic Disease, 2018, 41, 1189-1203.	1.7	27
5	Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. Journal of Inherited Metabolic Disease, 2018, 41, 209-219.	1.7	114
6	Precision newborn screening for lysosomal disorders. Genetics in Medicine, 2018, 20, 847-854.	1.1	99
7	Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease. International Journal of Neonatal Screening, 2018, 4, 41.	1.2	17
8	Newborn screening in mucopolysaccharidoses. Italian Journal of Pediatrics, 2018, 44, 126.	1.0	50
9	Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. International Journal of Molecular Sciences, 2018, 19, 3726.	1.8	63
10	The new frame for Mucopolysaccharidoses. Italian Journal of Pediatrics, 2018, 44, 117.	1.0	6
11	Pharmacological treatment of pediatric Gaucher disease. Expert Review of Clinical Pharmacology, 2018, 11, 1183-1194.	1.3	20
12	International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome. Acta Paediatrica, International Journal of Paediatrics, 2018, 107, 2059-2065.	0.7	10
13	GNPTAB c.2404Câ€‰>â€‰T nonsense mutation in a patient with mucolipidosis III alpha/beta: a case report. BMC Medical Genetics, 2018, 19, 162.	2.1	2
14	Current State of the Art of Newborn Screening for Lysosomal Storage Disorders. International Journal of Neonatal Screening, 2018, 4, 24.	1.2	16
15	Incidence of 4 Lysosomal Storage Disorders From 4 Years of Newborn Screening. JAMA Pediatrics, 2018, 172, 696.	3.3	43
16	Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet Journal of Rare Diseases, 2018, 13, 84.	1.2	50
17	Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.2	47
18	Updates in Newborn Screening. Pediatric Annals, 2018, 47, e187-e190.	0.3	21

#	Article	IF	Citations
19	Î±â€Galactosidase Aâ€deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease. FASEB Journal, 2019, 33, 418-429.	0.2	24
20	The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants. Genetics in Medicine, 2019, 21, 631-640.	1.1	113
21	Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey. Advances in Therapy, 2019, 36, 2866-2880.	1.3	17
22	Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy. International Journal of Neonatal Screening, 2019, 5, 24.	1.2	45
23	Rats deficient in Î±-galactosidase A develop ocular manifestations of Fabry disease. Scientific Reports, 2019, 9, 9392.	1.6	9
24	Population-Based Newborn Screening for Mucopolysaccharidosis Type II in Illinois: The First Year Experience. Journal of Pediatrics, 2019, 214, 165-167.e1.	0.9	14
25	Niemann-Pick disease A or B in four pediatric patients and SMPD1 mutation carrier frequency in the Mexican population. Annals of Hepatology, 2019, 18, 613-619.	0.6	6
26	The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening. Journal of Pediatrics, 2019, 211, 193-200.e2.	0.9	22
27	Genotypeâ€phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry. Clinical Genetics, 2019, 96, 281-289.	1.0	54
28	Newborn Screening for Lysosomal Storage Disorders: Methodologies for Measurement of Enzymatic Activities in Dried Blood Spots. International Journal of Neonatal Screening, 2019, 5, 1.	1.2	38
29	Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clinical Genetics, 2019, 96, 107-117.	1.0	87
30	The Role of Technology in Newborn Screening. North Carolina Medical Journal, 2019, 80, 49-53.	0.1	8
31	Hematopoietic cell transplantation for severe MPS I in the first six months of life: The heart of the matter. Molecular Genetics and Metabolism, 2019, 126, 117-120.	0.5	6
32	Recent trends in mucopolysaccharidosis research. Journal of Human Genetics, 2019, 64, 127-137.	1.1	31
33	Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION. Molecular Genetics & Genomic Medicine, 2019, 7, e564.	0.6	65
34	Progress in the understanding and treatment of Fabry disease. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129437.	1.1	73
35	Expanding the clinical utility of glucosylsphingosine for Gaucher disease. Journal of Inherited Metabolic Disease, 2020, 43, 558-563.	1.7	26
36	High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients. Clinica Chimica Acta, 2020, 501, 234-240.	0.5	11

#	Article	IF	Citations
37	The role of Immunity in Fabry Disease and Hypertension: A Review of a Novel Common Pathway. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 539-546.	1.0	9
38	Second-Generation Pharmacological Chaperones: Beyond Inhibitors. Molecules, 2020, 25, 3145.	1.7	31
39	Newborn Screening for Mucopolysaccharidosis I: Moving Forward Learning from Experience. International Journal of Neonatal Screening, 2020, 6, 91.	1.2	8
40	Fabry Disease practice resource: Focused revision. Journal of Genetic Counseling, 2020, 29, 715-717.	0.9	1
41	Fabry disease screening in high-risk populations in Japan: a nationwide study. Orphanet Journal of Rare Diseases, 2020, 15, 220.	1.2	9
42	A Newborn Screening, Presymptomatically Identified Infant With Late-Onset Pompe Disease: Case Report, Parental Experience, and Recommendations. International Journal of Neonatal Screening, 2020, 6, 22.	1.2	7
43	Digital Microfluidics in Newborn Screening for Mucopolysaccharidoses: A Progress Report. International Journal of Neonatal Screening, 2020, 6, 78.	1.2	7
44	Report of Five Years of Experience in Neonatal Screening for Mucopolysaccharidosis Type I and Review of the Literature. International Journal of Neonatal Screening, 2020, 6, 85.	1.2	12
45	A highly multiplexed biochemical assay for analytes in dried blood spots: application to newborn screening and diagnosis of lysosomal storage disorders and other inborn errors of metabolism. Genetics in Medicine, 2020, 22, 1262-1268.	1.1	18
46	Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy. Clinica Chimica Acta, 2020, 508, 179-184.	0.5	6
47	Estimated birth prevalence of Menkes disease and ATP7A-related disorders based on the Genome Aggregation Database (gnomAD). Molecular Genetics and Metabolism Reports, 2020, 24, 100602.	0.4	20
48	Toward newborn screening of cerebrotendinous xanthomatosis: results of a biomarker research study using 32,000 newborn dried blood spots. Genetics in Medicine, 2020, 22, 1606-1612.	1.1	25
49	Validation of Liquid Chromatography-Tandem Mass Spectrometry-Based 5-Plex Assay for Mucopolysaccharidoses. International Journal of Molecular Sciences, 2020, 21, 2025.	1.8	2
50	Newborn Screening for Pompe Disease in Illinois: Experience with 684,290 Infants. International Journal of Neonatal Screening, 2020, 6, 4.	1.2	19
51	A Comparative Effectiveness Study of Newborn Screening Methods for Four Lysosomal Storage Disorders. International Journal of Neonatal Screening, 2020, 6, 44.	1.2	23
52	Screening for Fabry Disease in Patients With Juvenile Systemic Lupus Erythematosus. Archives of Rheumatology, 2020, 35, 7-12.	0.3	4
53	Lessons Learned from Pompe Disease Newborn Screening and Follow-up. International Journal of Neonatal Screening, 2020, 6, 11.	1.2	20
54	The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia. BMC Nephrology, 2020, 21, 58.	0.8	9

#	Article	IF	Citations
55	Lysosomal Ceramide Metabolism Disorders: Implications in Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2020, 9, 594.	1.0	31
56	Development of a newborn screening tool for mucopolysaccharidosis type I based on bivariate normal limits: Using glycosaminoglycan and alphaâ€Lâ€iduronidase determinations on dried blood spots to predict symptoms. JIMD Reports, 2020, 52, 35-42.	0.7	11
57	Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction. International Journal of Neonatal Screening, 2020, 6, 2.	1.2	23
58	Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I. International Journal of Neonatal Screening, 2020, 6, 10.	1.2	32
59	The N370S/R496H genotype in type 1 Gaucher disease â€“ Natural history and implications for pre symptomatic diagnosis and counseling. Molecular Genetics and Metabolism Reports, 2020, 22, 100567.	0.4	2
60	Newborn screening for Fabry disease in the western region of Japan. Molecular Genetics and Metabolism Reports, 2020, 22, 100562.	0.4	32
61	Newborn Screening for Pompe Disease. International Journal of Neonatal Screening, 2020, 6, 31.	1.2	28
62	Newborn screening of mucopolysaccharidoses: past, present, and future. Journal of Human Genetics, 2020, 65, 557-567.	1.1	16
63	Toward newborn screening of metachromatic leukodystrophy: results from analysis of over 27,000 newborn dried blood spots. Genetics in Medicine, 2021, 23, 555-561.	1.1	31
64	Mucopolysaccharidosis type I newborn screening: Importance of second tier testing for ethnically diverse populations. American Journal of Medical Genetics, Part A, 2021, 185, 134-140.	0.7	5
65	Prevalence of Lysosomal Storage Disorders. SSRN Electronic Journal, 0, , .	0.4	0
66	Lysosomal Storage Disorders. , 2021, , 563-682.		4
67	Epidemiology of Mucopolysaccharidoses Update. Diagnostics, 2021, 11, 273.	1.3	50
68	Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert Opinion on Pharmacotherapy, 2021, 22, 1489-1503.	0.9	10
70	Newborn Screening for Krabbe Diseaseâ€”Illinois Experience: Role of Psychosine in Diagnosis of the Disease. International Journal of Neonatal Screening, 2021, 7, 24.	1.2	11
71	Opinions of adults affected with laterâ€onset lysosomal storage diseases regarding newborn screening: A qualitative study. Journal of Genetic Counseling, 2021, 30, 1544-1558.	0.9	5
72	Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet Journal of Rare Diseases, 2021, 16, 241.	1.2	33
73	Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience. Biomolecules, 2021, 11, 951.	1.8	20

#	Article	IF	Citations
74	Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan. Molecular Genetics and Metabolism, 2021, 133, 277-288.	0.5	22
75	Diagnosis of Mucopolysaccharidoses and Mucolipidosis by Assaying Multiplex Enzymes and Glycosaminoglycans. Diagnostics, 2021, 11, 1347.	1.3	5
76	The future of newborn screening for lysosomal disorders. Neuroscience Letters, 2021, 760, 136080.	1.0	17
77	Detecting lysosomal storage disorders by glycomic profiling using liquid chromatography mass spectrometry. Molecular Genetics and Metabolism, 2021, 134, 43-52.	0.5	11
78	High-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review. Diagnostics, 2021, 11, 1779.	1.3	5
79	Health care practitioners' experience-based opinions on providing care after a positive newborn screen for Pompe disease. Molecular Genetics and Metabolism, 2021, 134, 20-28.	0.5	5
80	<scp>MPS</scp> I: Early diagnosis, bone disease and treatment, where are we now?. Journal of Inherited Metabolic Disease, 2021, 44, 1289-1310.	1.7	8
81	Plasma lyso-sphingomyelin levels are positively associated with clinical severity in acid sphingomyelinase deficiency. Molecular Genetics and Metabolism Reports, 2021, 28, 100780.	0.4	13
82	Mucopolysaccharidoses. , 2021, , 501-562.		0
83	Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. Scientific Reports, 2021, 11, 2594.	1.6	12
85	Neuropathic pain in a Fabry disease rat model. JCI Insight, 2018, 3, .	2.3	46
86	Mutational spectrum of SMPD1 gene in Pakistani Niemann-Pick disease patients. Pakistan Journal of Medical Sciences, 2020, 36, 479-484.	0.3	9
87	Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. PLoS ONE, 2020, 15, e0233460.	1.1	9
88	The combined use of enzyme activity and metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type I. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2063-2072.	1.4	12
89	Newborn screening for lysosomal disorders in Brazil: A pilot study using customized fluorimetric assays. Genetics and Molecular Biology, 2020, 43, e20180334.	0.6	10
90	Laboratory Diagnosis of Lysosomal Diseases: Newborn Screening to Treatment. , 2020, 41, 53-66.		8
91	Storage diseases with hypertrophic cardiomyopathy phenotype. Global Cardiology Science & Practice, 2018, 2018, 28.	0.3	6
92	Fabryâ€™s disease in cardiological aspect. Medical Alphabet, 2020, , 22-27.	0.0	1

#	Article	IF	Citations
93	Neonatal Screening. , 2022, , 57-86.		0
94	Prevalence of lysosomal storage disorders in Australia from 2009 to 2020. The Lancet Regional Health - Western Pacific, 2022, 19, 100344.	1.3	12
95	Management of Mucopolysaccharidosis Type I in Saudi Arabia: Insights from Saudi Arabia. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 304-309.	0.1	2
96	Newborn screening of mucopolysaccharidosis type I. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 257-277.	2.7	2
97	Early clinical phenotype of late onset Pompe disease: Lessons learned from newborn screening. Molecular Genetics and Metabolism, 2022, 135, 179-185.	0.5	17
98	Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Molecular Genetics and Metabolism, 2022, 135, 154-162.	0.5	10
100	The Mucopolysaccharidoses. , 2022, , 1267-1286.		2
101	ä¸²è•"è^¨è°±æ³•ç›æŸ¥æ–°ç"Ÿå„¿æ°¶é…¶ä½"è´®ç§¯ç—‡é…¶æ´»æ€§å^‡å€¼ç¡®å»»ç««. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zh	0.1	3
102	The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?. Molecular Genetics and Metabolism, 2022, 136, 4-21.	0.5	18
103	Newborn screening for Gaucher disease in Japan. Molecular Genetics and Metabolism Reports, 2022, 31, 100850.	0.4	4
104	Novel Management and Screening Approaches for Haematological Complications of Gaucherâ€™s Disease. Journal of Blood Medicine, 2021, Volume 12, 1045-1056.	0.7	3
105	Fabry Disease in Slovakia: How the Situation Has Changed over 20 Years of Treatment. Journal of Personalized Medicine, 2022, 12, 922.	1.1	0
106	Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses. , 2022, , 735-764.		1
107	Late-onset Fabry disease: the cardiac sequela. BMJ Case Reports, 2022, 15, e247917.	0.2	0
108	Early diagnosis of Gaucher disease in Korean patients with unexplained splenomegaly: a multicenter observational study. Blood Research, 2022, 57, 207-215.	0.5	0
110	Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis. Journal of Pediatric Hematology/Oncology, 2023, 45, 181-188.	0.3	5
111	Prevalence of Fabry disease-causing variants in the UK Biobank. Journal of Medical Genetics, 2023, 60, 391-396.	1.5	10
112	Development of a clinically validated in vitro functional assay to assess pathogenicity of novel GAA variants in patients with Pompe disease identified via newborn screening. Frontiers in Genetics, 0, 13, .	1.1	4

#	Article	IF	Citations
113	Newborn screening and the recommended uniform screening panel: Optimal submissions and suggested improvements based on an advocacy organization's decadeâ€long experience. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2022, 190, 156-161.	0.7	3
114	Newborn screening for Fabry disease in Oregon: Approaching the iceberg of <scp>A143T</scp> and variants of uncertain significance. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2022, 190, 206-214.	0.7	3
115	Detection of diseaseâ€causing CFTR variants in state newborn screening programs. Pediatric Pulmonology, 2023, 58, 465-474.	1.0	12
116	Newborn screening for Pompe disease in Italy: Long-term results and future challenges. Molecular Genetics and Metabolism Reports, 2022, 33, 100929.	0.4	8
117	A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease. International Journal of Neonatal Screening, 2022, 8, 61.	1.2	6
118	Liquid Chromatographyâ€“Tandem Mass Spectrometry in Newborn Screening Laboratories. International Journal of Neonatal Screening, 2022, 8, 62.	1.2	8
119	Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review. Journal of Clinical Medicine, 2023, 12, 85.	1.0	12
120	The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants. Orphanet Journal of Rare Diseases, 2023, 18, .	1.2	4
121	Metabolomics used in clinical diagnosis related to newborn screening. , 2023, , 121-171.		0
122	The Niemann-Pick type diseases â€“ A synopsis of inborn errors in sphingolipid and cholesterol metabolism. Progress in Lipid Research, 2023, 90, 101225.	5.3	8
123	Importance to include differential diagnostics for acid sphingomyelinase deficiency (ASMD) in patients suspected to have to Gaucher disease. Molecular Genetics and Metabolism, 2023, 139, 107563.	0.5	1
124	The <scp>D409H</scp> variant in <scp> GBA1 </scp> : Challenges in predicting the Gaucher phenotype in the newborn screening era. American Journal of Medical Genetics, Part A, 0, , .	0.7	0